UA88481U - Применение фармацевтической композиции или ее фармацевтически приемлемых солей как кардиопротекторное лекарственное средство - Google Patents
Применение фармацевтической композиции или ее фармацевтически приемлемых солей как кардиопротекторное лекарственное средство Download PDFInfo
- Publication number
- UA88481U UA88481U UAU201211511U UAU201211511U UA88481U UA 88481 U UA88481 U UA 88481U UA U201211511 U UAU201211511 U UA U201211511U UA U201211511 U UAU201211511 U UA U201211511U UA 88481 U UA88481 U UA 88481U
- Authority
- UA
- Ukraine
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- angina
- acceptable salts
- post
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 150000003839 salts Chemical class 0.000 title claims abstract description 17
- 229940045200 cardioprotective agent Drugs 0.000 title claims abstract 3
- 239000012659 cardioprotective agent Substances 0.000 title claims abstract 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 14
- -1 1 - adamantylethyloxy Chemical group 0.000 claims description 11
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 11
- 210000004165 myocardium Anatomy 0.000 claims description 10
- 208000029078 coronary artery disease Diseases 0.000 claims description 9
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 206010002383 Angina Pectoris Diseases 0.000 claims description 7
- 230000002503 metabolic effect Effects 0.000 claims description 7
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 6
- 206010061216 Infarction Diseases 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000000306 recurrent effect Effects 0.000 claims description 6
- 230000002537 thrombolytic effect Effects 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 5
- 206010002388 Angina unstable Diseases 0.000 claims description 5
- 208000007718 Stable Angina Diseases 0.000 claims description 5
- 208000007814 Unstable Angina Diseases 0.000 claims description 5
- 238000002399 angioplasty Methods 0.000 claims description 5
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 5
- 229960004592 isopropanol Drugs 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 201000002638 post-cardiac arrest syndrome Diseases 0.000 claims description 5
- 206010058144 Postinfarction angina Diseases 0.000 claims description 4
- 201000009101 diabetic angiopathy Diseases 0.000 claims description 4
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000033764 rhythmic process Effects 0.000 claims description 4
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 2
- PHPZOAWILSNRQG-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethoxy]-3-morpholin-4-ylpropan-2-ol Chemical compound C1C(C2)CC(C3)CC2CC13CCOCC(O)CN1CCOCC1 PHPZOAWILSNRQG-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 description 13
- 210000004413 cardiac myocyte Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000036770 blood supply Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 2
- 230000003293 cardioprotective effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000867418 Morion Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000141 anti-hypoxic effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000008599 nitrosative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Применение фармацевтической композиции, которая включает 1-адамантилэтилокси 3-морфолино-2-пропанол или ее фармацевтически приемлемые соли для парантерального применения как кардиопротекторное средство.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201211511U UA88481U (ru) | 2012-10-05 | 2012-10-05 | Применение фармацевтической композиции или ее фармацевтически приемлемых солей как кардиопротекторное лекарственное средство |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201211511U UA88481U (ru) | 2012-10-05 | 2012-10-05 | Применение фармацевтической композиции или ее фармацевтически приемлемых солей как кардиопротекторное лекарственное средство |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA88481U true UA88481U (ru) | 2014-03-25 |
Family
ID=56267596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU201211511U UA88481U (ru) | 2012-10-05 | 2012-10-05 | Применение фармацевтической композиции или ее фармацевтически приемлемых солей как кардиопротекторное лекарственное средство |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA88481U (ru) |
-
2012
- 2012-10-05 UA UAU201211511U patent/UA88481U/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spoelstra-de Man et al. | Making sense of early high-dose intravenous vitamin C in ischemia/reperfusion injury | |
| CA2829101C (en) | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia | |
| US20110312902A1 (en) | Cytoprotective thereapeutic agents for the prevention of reperfusion injury following ischemic stroke | |
| Zhang et al. | The pathological mechanisms and potential therapeutic drugs for myocardial ischemia reperfusion injury | |
| Chen et al. | Intracoronary administration of anisodamine and nicorandil in individuals undergoing primary percutaneous coronary intervention for acute inferior myocardial infarction: a randomized factorial trial | |
| Chen et al. | Protective mechanisms of hydrogen sulfide in myocardial ischemia | |
| CN110420205B (zh) | 3-羟基-3’,4’-二羟基-丁酸苯乙酯在制备改善主动脉内皮细胞功能药物中的应用 | |
| UA110336C2 (uk) | Фармацевтична композиція 1-адамантилетилокси-3-морфоліно-2-пропанолу або його фармацевтично прийнятних солей як кардіопротекторний лікарський засіб | |
| UA88481U (ru) | Применение фармацевтической композиции или ее фармацевтически приемлемых солей как кардиопротекторное лекарственное средство | |
| CN103169694B (zh) | 正丁烯基苯酞在制造用于治疗肝损伤和改善肝功能的药物中的用途及药物组合物 | |
| UA110366C2 (uk) | Фармацевтична композиція 1-адамантилетилокси-3-морфоліно-2-пропанолу або його фармацевтично прийнятних солей для лікування кардіоваскулярної патології | |
| UA105475C2 (ru) | Фармацевтическая композиция, которая содержит 1-адамантилэтокси-3-диэтиламино-2-пропанол гидрохлорид или его фармацевтически приемлемые соли, для создания лекарственных средств для лечения кардиоваскулярной патологии | |
| Kitakaze | How to mediate cardioprotection in ischemic hearts—accumulated evidence of basic research should translate to clinical medicine | |
| Li et al. | Empagliflozin, a sodium‐glucose cotransporter inhibitor enhancing mitochondrial action and cardioprotection in metabolic syndrome | |
| Asif | A brief survey of clinically used various cardiovascular agents | |
| Aramendi et al. | Effect of half-molar sodium lactate infusion on biochemical parameters in critically ill patients | |
| Singh et al. | Evolutionary Unmasking Resuscitative Therapeutics Potential of Centhaquin Citrate in Hypovolemic Shock | |
| CN110664799B (zh) | 用于治疗脑缺血的药物组合物及其应用 | |
| Sharma et al. | Elucidation and Possible Mechanism of Action of Cardio Protective Drugs viz. Ranolazine, Ivabradine, Cilostazol and Inamrinone in Ischemic Reperfusion Induced Cardiac Injury | |
| EP3806839B1 (en) | Retinoic acid receptor-beta2 agonist with cardioprotective effects | |
| Govender | Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: An evaluation of the protective role of melatonin. | |
| Kumari et al. | Preclinical and Clinical Aspects of I/R Injuries | |
| Al-Mosawi | The uses of pentoxifylline in cardiology and hypertension | |
| Han et al. | Research Article Neuroprotective Effects of Early Hypothermia Induced by Phenothiazines and DHC in Ischemic Stroke | |
| Koju et al. | Coenzyme II and Heart Disease |